Tolerability and side-effects of post-exposure prophylaxis for HIV infection

被引：69

作者：

Parkin, JM ^{[1
]}

Murphy, M

Anderson, J

El-Gadi, S

Forster, G

Pinching, AJ

机构：

[1] Bartholomews & London NHS Trust, Infect & Immun Clin Grp, London, England

[2] Homerton Hosp NHS Trust, Dept Sexual Hlth, London, England

[3] St Bartholomews & London Sch Med & Dent, Dept Immunol, London, England

来源：

LANCET | 2000年 / 355卷 / 9205期

关键词：

D O I：

10.1016/S0140-6736(99)05005-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A study of HIV post-exposure prophylaxis in 28 recipients showed that indinavir-containing regimens were poorly tolerated. This finding has implications for compliance and efficacy of the currently recommended combinations.

引用

页码：722 / 723

页数：2

共 5 条

[1]

[Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P1

[2]

*CDC, 1995, MMWR-MORBID MORTAL W, V44, P929

[3]

*DEP HLTH, 1997, GUID POST PEX PROPH

[4] A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].

Hammer, SM ;

Squires, KE ;

Hughes, MD ;

Grimes, JM ;

Demeter, LM ;

Currier, JS ;

Eron, JJ ;

Feinberg, JE ;

Balfour, HH ;

Dayton, LR ;

Chodakewitz, JA ;

Fischl, MA .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733

[5] Transmission of antiretroviral-drug-resistant HIV-1 variants [J].

Yerly, S ;

Kaiser, L ;

Race, E ;

Bru, JP ;

Clavel, F ;

Perrin, L .

LANCET, 1999, 354 (9180) :729-733

← 1 →